InvestSMART

Actinogen Medical Limited (ASX:ACW)

ALERT: Price-sensitive ASX Announcement for ACW
Current share price for ACW : $0.059 0.016 (37.21%)+
Announcement
Release
12 Nov 2025 11:07AM
Price at Release
$0.043
Full Release
download
Summary
Actinogen Medical Limited announced a positive recommendation from the first Data Monitoring Committee (DMC) meeting regarding its XanaMIA phase 2b/3 trial for Alzheimer's disease. The DMC, composed of independent clinical and statistical experts, reviewed safety data from 153 trial participants and decided to continue the trial without amendment. The efficacy of Xanamem®, the drug being tested, was not evaluated in this meeting. A future meeting is scheduled for January 2026 to assess both safety and efficacy using unblinded data from participants who have completed the treatment period. Actinogen is focused on developing therapies for neurological and neuropsychiatric diseases linked to elevated brain cortisol levels and is actively pursuing clinical trials for Alzheimer's and depression.
Key Points
  • Actinogen Medical receives positive recommendation from the first DMC meeting for XanaMIA trial.
  • DMC comprises independent experts and assessed safety data from 153 participants.
  • The trial will continue without amendments; efficacy was not evaluated at this time.
  • A future DMC meeting will evaluate efficacy and safety in January 2026 using unblinded data.
  • Actinogen focuses on therapies for diseases linked to brain cortisol, including Alzheimer's and depression.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.